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Abstract 
This review summarizes drug discovery efforts on mGluR2 positive allosteric modulators 
(PAMs) from 2000 to 2013. Medicinal chemistry programs and the identified 21 chemotypes 
are analyzed and compared in terms of their biological activity and ligand efficiency. 
Comparative analysis of ligand efficiency metrics including ligand efficiency and lipophilic 
ligand efficiency allowed us to identify the most promising chemotypes. The perspective of 
their clinical development was evaluated in the light of recent human data. 
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Introduction 
Glutamate is the major excitatory neurotransmitter that plays a role in eliciting and 
modulating synaptic responses. These processes involve ionotropic (AMPA, NMDA, kainate) 
and metabotropic receptors. Up to now eight metabotropic glutamate (mGluR) receptors 
have been described and characterized [1] and were classified into three subgroups based 
on their similarity in sequence, signaling and pharmacology [2]. Most of the drug discovery 
interest has been focused to Group I and Group II targets that include mGluR1/mGluR5 and 
mGluR2/mGluR3 receptors, respectively. Inhibition of mGluR1 receptors has been connected 
to anxiolytic [3] and analgesic [4] effects. Negative modulation of mGluR5 receptors found to 
be beneficial in the animal models of anxiety, depression, Fragile-X and autism spectrum 
disorder (ASD) [5,6]. mGluR5 positive allosteric modulators (PAMs) are believed to be 
attractive as a potential pharmacotherapy of schizophrenia [7]. 
In addition to mGluR5 PAMs compounds targeting Group II receptors are also considered as 
a promising treatment option for schizophrenia.  mGluR2 and mGluR3 receptors impact the 
glutamatergic transmission in certain brain areas implicated in the pathophysiology of 
schizophrenia.  These neurobiological observations have been validated in the experimental 
models of schizophrenia indicating that Group II mGluR agonists are effective in a number of 
antipsychotic animal models [8-11]. One of the best characterized compounds from this class 
is the mGluR2/3 receptor agonists LY404039 that showed remarkable efficacy in animal 
models of schizophrenia [12] and anxiety [13]. The suboptimal pharmacokinetics of 
LY404039 prompted the Lilly research team developing its methionine amide prodrug 
LY2140023 that were found to be effective in a phase 2 study in schizophrenia patients [14, 
15]. Although LY2140023 was less effective than the comparator olanzapine but its effect 
was separated from the placebo and more importantly no weight gain was observed during 
the treatment period. These promising results, however, were followed by two negative 
studies. The first one was claimed to be an inconclusive study since neither the effect of 
LY2140023 nor that of the active control olanzapine could be separated from placebo [16]. 
In the second negative study LY2140023 was tested against placebo and risperidone as an 
active control in two doses and two populations one of them preselected using genetic 
markers. Unlike the active comparator risperidone unfortunately LY2140023 did not show 
efficacy compared to placebo in either population or dose.  
 
The relative contribution of mGluR2 and mGluR3 receptors in the antipsychotic 
pharmacology of mGluR2/3 agonists has yet to be fully elucidated. Due to the high level of 
conservation of the orthosteric (agonist) binding site of mGluRs, developing subtype-specific 
agonists has proven to be difficult. To date no agonist has been reported to discriminate 
between mGluR2 and mGluR3. However, in studies using transgenic mice lacking the 
mGluR2 or mGluR3 receptor, it has been shown that the antipsychotic effects of the 
mGluR2/3 receptor agonists in the PCP and amphetamine models of psychosis are mediated 
through the activation of mGluR2 and not of mGluR3 receptors [17,18]. 
One alternative approach to direct-acting selective mGluR2 receptor agonists is the use of 
subtype-selective positive allosteric modulators (PAMs). These ligands do not activate the 
mGluR2 receptor per se but act at an allosteric binding site on the receptor to potentiate 
glutamate-induced activation of this receptor. Since a potentiator with no inherent agonist 
activity would only function in the presence of the endogenous agonist, the receptor would 
not be activated continuously, avoiding receptor desensitization which often occurs after 
repeated dosing of orthosteric agonists [19-20]. In addition, the allosteric binding sites on 
glutamate receptors might sufficiently be different as to make subgroup selectivity 
achievable [21]. In fact, the preclinical proof of concept was achieved by LY487379, the first 
mGluR2 receptor–specific PAM [22] showing efficacy in animal models of schizophrenia [23, 
24]. More recently the Addex-J&J team reported the first successful clinical proof of concept 
study with ADX-71149 (also known as JNJ-4041183). This phase 2a study was separated into 
A and B parts investigating ADX-71149 as monotherapy and adjunctive therapy, respectively. 
ADX-71149 was found to be safe and well-tolerated while in the part B setup demonstrated 
efficacy on residual negative symptoms [25]. 
The promising clinical results with the first mGluR2 PAM in man prompted us collecting 
recently published series of positive allosteric modulators for mGluR2 receptor with primary 
pharmacology data (general assay conditions are available as supplementary material) and 
review their potential in psychiatric indications. 
 
Medicinal chemistry of mGlu2 positive allosteric modulators 
mGluR2 positive allosteric modulators has been reviewed in 2005 [21] and 2009 [26].  Here 
we provide a comprehensive overview of mGluR2 PAMs published thirteen years up to 2013. 
Analyzing the major competitors on the field AstraZeneca, Janssen and Merck are the key 
players (Table 1) but pharma companies filed almost a constant amount of patent 
applications during the last five years (please note that data for 2013 is incomplete).   
  2001 2004 2006 2007 2008 2009 2010 2011 2012 2013 Total 
Lilly 1  2    1    4 
Merck  1 3   3 3 5 7  22 
AZ  1 2 5 5 1  1   15 
Janssen   2 1 3 4 6  4  20 
Pfizer    2 2 1     4 
Sanofi     1 1  3   5 
Abott     1   2   3 
Organon        1   1 
Sanford-
Burnham 
       1   1 
Taisho          2 2 
Dainippon          1 1 
Total 1 2 9 8 12 10 10 14 11 3 78 
 
Table 1. Patent applications filed on mGlu2 positive allosteric modulators  
 
Here we present a comprehensive review of compound series reported as mGluR2 positive 
allosteric modulators. We discuss the series in compound families that helps to understand 
the structure-activity relationship and useful to identify key pharmacophore elements.  
 
1. Sulfonamides 
 
LY487379 (1) was the first reported highly active and selective mGluR2 positive allosteric 
modulator (Figure 1). It was identified by in-house high throughput screening (HTS) and 
subsequent medicinal chemistry optimization at Eli Lilly in the early 2000s [27]. Compound 1 
is a potent mGluR2 PAM with an EC50 value of 270 nM in an mGluR FLIPR assay [28]. 
LY487379 was characterized in a series of in vivo pharmacological tests [28,29] and showed 
activity which suggested potential antipsychotic activity in humans. A series of compounds 
closely-related to LY487379 was also disclosed in a patent application from Merck [30]. This 
series of sulfonamide derivatives is exemplified by compound 2 showing an EC50 value of 840 
nM in a GTPγS binding assay [31] (Figure 1).  
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Figure 1. mGluR2 PAM sulfonamides 
 
2. Indanones 
 
In 2004 researchers at Merck published two patent applications describing indanone 
derivatives. The first application disclosed indanones typically substituted with cyclopentyl at 
C-2, methyl or chloro at C-6 and C-7 and phenyl tertazoles and biaryl acids, as lipophilic end 
groups at C-5 [32]. Examples of this application indicated to have an EC50 value less than 10 
µM in a GTPγS binding assay. Preferred compound possess an EC50 less than 1 µM, although 
no specific potency values are given. Compound 3, also known as BINA [33] is a 
representative structure of this indanone series (Figure 2). BINA, together with LY487379, is 
among the first mGluR2 potentiators showing antipsychotic- and anxiolytic like effects in 
vivo [34,35]. Detailed SAR of this series is also published separately in two medicinal 
chemistry papers [33,36]. The second application from this series discloses closely-related 
indanones with 4-thiopyridine structure elements at C-6 [37], as exemplified with compound 
4. This compound is a potent mGluR2 PAM with an EC50 value of 225 nM in a GTPγS binding 
assay and significant effect in a ketamine-induced hyperlocomotion model in rats at the dose 
of 40 mg/kg, i.p. [36]. 
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Figure 2. mGluR2 PAM indanones     
 
 3. Arylketones 
 
Researchers at Merck disclosed novel chemical entities showing significant activity on 
mGluR2 receptor in two patent applications published in 2002 and 2004, respectively [37,38] 
(Figure 3). The first in a series of applications disclosed such arylketone derivatives where 
acetophenones were linked with an aryl ether linker to an acidic phenyl tetrazole scaffold. 
Representative compound 5, identified by in-house high-throughput screening had an EC50 
value of 328 nM and found to be selective over other mGluR receptors [39]. The structure–
activity relationships (SAR) of these derivatives have been reported in a separate paper [40]. 
In the second patent application Merck disclosed acetophenone derivatives with improved 
brain penetration [38]. Potency and pharmacokinetic data of these derivatives have also 
been reported [41,42].  Compound 6, bearing a coumarinone scaffold instead of phenyl 
tetrazole moiety showed improved brain/plasma ratio compared to the original HTS hit 5, 
nevertheless, the mGluR2 affinity was slightly decreased (GTPγS EC50 = 1400 nM).  
Researchers at Lilly have also identified a closely-related series of arylketone derivatives 
using a benzyl ether linkage [43]. These compounds are dual-acting compounds; 
potentiators of mGluR2 and antagonists of leukotriene Cys-1 receptor. These derivatives are 
exemplified by compound 7 with an mGluR2 EC50 less than 350 nM and CysLT1 IC50 less than 
150 nM in a FLIPR assay.  
In a second application [44], consisting of 155 specific examples, a benzhydril linkage is used. 
The preferred compound is 8, possesses an mGluR2 EC50 less than 100 nM and CysLT1 IC50 
less than 750 nM in a FLIPR assay. Compound 8, also known as LY2300559 had been in Phase 
II development for migraine prophylaxis but the study was terminated due to transaminase 
elevations [45]. 
In a third application novel arylketone derivatives containing an imidazole carboxamide 
function have been disclosed [46]. These derivatives are exemplified with compound 9, as a 
potent mGluR2 PAM with an EC50 value of 26 nM in FLIPR assay. A detailed in vivo profile of 
this compound, also known as THIIC, was given in a separate literature [47].  
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Figure 3. mGluR2 PAM arylketones 
 
4. Pyridones 
 
Janssen Pharmaceutical and partner Addex Therapeutics have filed 10 patent applications 
disclosing pyridones (unsubstituted, 3-cyano and 3-chloro pyridones) chemotypes. 
In their initial case, consisting of around 370 examples, discloses N-benzyl pyridones 
substituted at C-4 or C-5 with aryl moieties [48]. Exemplified compounds have different 
substitution pattern around the benzylic and aryl groups. Preferred compounds possess EC50 
values less than 1 µM in a GTPγS binding assay, including compound 10 (Figure 4). Detailed 
SAR of this chemotype has been reported in a separate paper [49]. Compound 10 displayed 
good brain levels after i.p. administration and comparable activity to a reference PAM, 
LY487379, in the in vivo Phencyclidine-Induced Hyperlocomotion (PCP-HL) assay. 
Janssen/Addex identified the important role of the cyano substituent at position 3 on the 
pyridine core. Thus, in 2006 and 2007 four patent applications have been published 
disclosing these 3-cyanopyridone derivatives [50,51,52,53].  
In the first application examples of pyridones substituted at N-1 by a lipophilic alkyl chain 
and substituted at C-4 by an aryl or N-linked heterocycles, often substituted at position 4 
with an aryl ring are described. The preferred example of this application is compound 11, 
with an EC50 value of 320 nM in a GTPγS binding assay [50]. A detailed pharmacological 
profile of compound 11, also known as JNJ40068782 and its radioligand [3H]JNJ40068782 has 
been recently reported in literature [54]. The compound has influenced rat sleep-wake 
organization by decreasing rapid eye movement sleep with a lowest active dose of 3 mg/kg 
p.o. In addition, JNJ-40068782 also reversed PCP-HL with an ED50 of 5.7 mg/kg s.c. in mice.  
In the second case nine examples of pyridones substituted at C-4 by 4-phenyl piperidines are 
described. These compounds are exemplified by compound 12 showing an EC50 value of 174 
nM in a GTPγS binding assay [51]. In the other two cases of 3-cyanipyridones C-4 biaryl 
ethers are disclosed. Examples of these applications are compounds 13 [52] and 14 [53] with 
EC50 values of 138 nM and 282 nm, respectively. By parallel filings Janssen/Addex 
demonstrated the equipotency of the chloro- and cyano substituent at position 3 on the 
pyridone scaffold (compound 15, 16 and 17) [55,56,57]. 
In 2010 further two patent applications were disclosed in the field of 3-chloro pyridones. In 
the first case 3-azabyciclo[3.1.0.]hexyl side chain is used at C-4 position. A preferred 
compound of this invention is 18 with an EC50 value of 89 nM [58]. The second application 
discloses indole and benzomorpholine heterocycles, as lipophilic side chains. These 
derivatives are exemplified by 19 showing an EC50 value of 76 nM [59].  
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Figure 4. mGluR2 PAM pyridones 
 
5. Isoindolones 
 
Researchers at AstraZeneca/NPS pharmaceuticals disclosed numerous isoindolone 
derivatives as novel scaffold showing significant activity as mGluR2 potentiators (Figure 5). 
The first disclosure in 2006 [60] included isoindolones typically substituted with a 4-
trifluoromethoxybenzyl group at N-1, a chloro or methyl substituent at C-7 and a heterocycle 
linked to the central scaffold. Among the preferred seven examples compound 20 is the 
most potent one with an EC50 value of 40 nM in a GTPγS binding assay. Further optimization 
of this scaffold was based primarily on the modification of the N-1 position. The second 
narrower application covering 19 compounds substituted with 4-phenoxybenzyl group at N-
1 and a heteroaryl ring at C-5. These compounds showed EC50 values less than 10 µM in a 
FLIPR or GTPγS binding assay, as compound 21 [61]. In parallel with this application 
AstraZeneca covered the analogues of the previously reported compounds [60] exemplified 
with 20. The first set of compounds use a piperidine methyl moiety at N-1, while the other 
set use substitutedoxadiazoles at C-5 coupled directly to the isoindolone core. Compounds 
22 and 23 are the most potent ones among the 33 examples with EC50 values of 28 nM and 
75 nM, respectively [62]. Oxadiazole derivatives were further optimized by AstraZeneca and 
two patent applications filed in 2008 describing isomeric oxadiazoles [63,64]. In these 
focused applications (20 examples) hERG and solubility data are also presented for selected 
compounds (see compounds 24 and 25 in Figure 5). Interestingly, in 2011, AstraZeneca filed 
a patent application claiming the preparation and polymorphs of compound 25 [65]. 
In another narrower case of 55 examples, isoindolones with a substituted alkyl or cycloalkyl 
substituent at N-1 and a 3-pyridyl or a phenyl ring substituted with 3-
methanesulfonamidophenyl at C-5 are disclosed [66]. These compounds are indicated to 
have mGluR2 EC50 values less than 10 μM in a FLIPR or GTPγS binding assay, although no 
specific potency values are given, including compound 26. In 2008 another patent 
application was filed by AstraZeneca describing also 3-methanesulfonamidophenyl 
derivatives equipped with a 4-azaisoindolone core [67]. In this focused application that 
discloses 20 examples potency values of 3 compounds are given. Among these the most 
potent compound, 27, showed an EC50 value of 160 nM. In another patent application of this 
series by AstraZeneca isoindolone hydrazides are disclosed [68]. The same substitution 
pattern can be seen in this application, exemplified with compound 28, which showed an 
EC50 value of 24 nM when tested for allosteric activation of human mGluR2 receptors 
expressed in CHO cells in a GTPγS assay. 
The last disclosure in this series by AstraZeneca included an isoxazole amide linked to the 
isoindolone scaffold at C-5 [69]. In this focused application hERG and solubility data are also 
presented for all 21 examples. The preferred compound is 29, being the most potent with an 
EC50 value of 36 nM and other parameters are also remarkable (hERG IC50 > 33 µM, solubility 
= 11.2 µM) (Figure 5). 
Researchers at Abbott have also filed 3 patent applications in the field of isoindolones 
(Figure 6). The first application discloses dual mGluR2 potentiators and 5-HT2A antagonists 
[70]. These dual acting isoindolone derivatives substituted with small alkyl groups at N-1 and 
aryl substituted pyrazol methyl ether at C-5, as exemplified with compound 30. Preferred 
compounds of this application have EC50 values less than 100 nM for mGluR2 potentiation in 
a FLIPR assay and Ki values less than 100 nM as antagonists in a binding assay, but no specific 
potency values are given. These dual-acting compounds may represent a new strategy based 
on the direct and functional interaction of the mGluR2 and 5-HT2A receptors. It has been 
shown that mGluR2 and 5-HT2A receptors form functional heterodimers and that mGluR2 
activation causes suppression of 5-HT2A-mediated signaling events [71,72]. Moreover, the 
responses elicited by hallucinogenic and non-hallucinogenic 5-HT2A agonists seem to differ 
in the intracellular signaling pathways involved [73,74] and mGluR2 activation might 
suppress the hallucinogenic pathway [71]. Interestingly, preliminary pharmacogenetic 
analysis of subjects treated with orthosteric mGluR2/3 agonist LY2140023 revealed a strong 
correlation between treatment response and 5-HT2A genotype of the patients [75]. 
Based on these observations it is assumed that potentiation of endogenous mGluR2 activity 
with subtype-selective positive allosteric modulators would specifically augment the 
suppression of hallucinogenic 5-HT2A signaling and thus might offer an effective therapy for 
schizophrenia by attenuation of cortical overexcitation. 
In the second application Abbott disclosed isoindolone derivatives substituted with a 3-
pyridil at C-5 linked by a methyloxy- or a methylamino spacer [76]. Preferred compounds 
have EC50 values less than 0.5 µM, such as compound 31.  
In the last application by Abbott [77] both isoindolones and isoquinolones are disclosed, in 
which a heterocyclic substituent is linked to the bicyclic core by a direct bond, methylene, 
oxygen or nitrogen spacer. Compounds from both chemotypes can be found within the six 
most active examples (EC50 less than 0.5 μM in a FLIPR assay) given (Figure 6, compound 32). 
In 2011, Organon also disclosed a series of isoindolone derivatives with different lipophilic 
side chains at C-5 position [78], suggesting that this part of the molecule is considerably 
variable. In this application 124 compounds are exemplified, of which 122 are isoindolone 
derivatives (2 are isoquinolinones). Preferred compounds have EC50 values less than 1 µM, 
such as compound 33. 
Researchers at the Sanford-Burham Medical Research Institute introduced some further 
analogs of isoindolones with modified lipophilic side chain at C-5 position [79]. The 
application also covers isoquinolinones, benzisothiazolones and benzisoxazolones, among 
which isoindolones were found to be the most potent. The representative compound of this 
invention is 34, with an EC50 value of 50 nM in a rat thallium flux assay (Figure 6). Detailed 
SAR around these chemotypes was given in a separate literature [80]. Compound 34, a close 
analogue of BINA, was shown to dose-dependently decrease nicotine self-administration in 
rats after oral administration. These data suggest the potential utility of mGluR2 PAMs for 
the treatment of nicotine dependence in humans. 
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Figure 5. mGluR2 PAM isoindolones 
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Figure 6. mGluR2 PAM isoindolones (continued) 
 
 
6. Oxazole derivatives 
 
6.1. Oxazolidinones 
 
The first oxazolidinone derivatives as mGluR2 potentiators were reported by 
AstaZeneca/NPS in 2007 [81]. This application exemplifies 125 N-benzylic oxazolidinones 
substituted with an aryl group at C-5 position, where the R configuration seems to be largely 
preferred. Specific potency values for 5 compounds are given, among which the most potent 
one is compound 35 with an EC50 value of 12 nM in a GTPγS binding assay (Figure 7). 
Optimization of this scaffold was based primarily on the modification of substituents at C-5. 
Thus, the second application from AstraZeneca discloses spirocyclic oxazolidinones [82]. 
Preferred compounds contain a cyclohexyl spirocycle as exemplified with compound 36, as 
the most potent one (GTPγS EC50 = 14 nM).  In 2009 researchers at Pfizer also disclosed 
oxazolidinone derivatives with methyl substituent at C-5 of the N-benzylic oxazolidinone 
core [83]. The invention also prefers the R configuration at C-5. Potency values are given for 
all synthesized 318 examples, among which compound 37 proved to be the most potent 
with an EC50 value of 4.96 nM in a FLIPR assay. Detailed SAR around this chemotype started 
from a HTS hit was given in a separate literature [84]. Modification of the alkylether moiety 
of 37 led to a series of biaryl analogs with improved physical properties, such as compound 
38 (FLIPR EC50 = 30 nM). This compound was found to be active in an in vivo 
methamphetamine-induced hyperlocomotion model in mice at a minimally effective dose 
(MED) of 10 mg/kg s.c [84]. 
Scientists at Merck have also published a series of oxazolidinones in 2009 [85]. Compounds 
of this invention have a smaller lipophilic side chain (aryl or benzyl) at N-3 but with large 
lipophilic substituents at C-5. A representative example from this series is compound 39 with 
EC50 value of 82 nM in a FLIPR assay. The hit-to-lead optimization of this oxazolidinone series 
is reported in a separate literature [86]. Compound 39 was shown to be brain penetrant and 
able to attenuate ketamine-induced psychomotor activity in rats similar to an mGluR2/3 
agonist, an assay sensitive to clinically therapeutic antipsychotics (Figure 7).  
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Figure 7. mGluR2 PAM oxazoles: oxazolidinones 
 
 
6.2. Oxazolobenzimidazoles 
 
In 2009 HTS-derived lead oxazolidinone was transformed into a novel series of 
oxazolobenzimidazoles by Merck (Figure 8). In this year two patent applications were filed 
[87,88]. Preferred compounds are substituted with heteroaryloxymethyl- or aryloxymethyl 
groups at C-2, where the R configuration seems to be largely preferred and small 
substituents at C-8 (cyano substitution is preferred). Representative examples of this 
invention are compound 40 [87] and 41 [88], with EC50 values of 21 nM and 12 nM, 
respectively. In 2010 Merck disclosed another oxazolobenzimidazole derivatives substituted 
with aliphatic groups at C-2 [89]. Compound 42 is a representative from this invention with 
an EC50 value of 11 nM. 
Detailed SAR and pharmacological investigation of oxazolobenzimidazoles are described in a 
separate publication [90].  
Optimization of the oxazolidinone through physical and pharmacokinetic properties led to 
the identification of potent and orally bioavailable compounds, such as compound 43, also 
known as TBPCOB. 
TBPCOB was shown to have robust activity in a PCP-HL model in rat, an assay responsive to 
clinical antipsychotic treatments for schizophrenia (Figure 8). 
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Figure 8. mGluR2 PAM oxazoles: oxazolobenzimidazoles 
 
6.3. Imidazooxazoles 
 
Very recently, researchers at Taisho have published a series of imidazooxazoles structurally 
related to previously reported oxazolidinones/oxazolobenzimidazoles [91] (Figure 9).   
The representative compound is 44, which potentiated ligand stimulation at rat and human 
mGluR2 receptors expressed in CHO cells with respective EC50 values of 215 and 317 nM in a 
GTPγS binding assay. It significantly attenuated methamphetamine-induced 
hyperlocomotion when administered to male Wistar rats at 30 mg/kg p.o. at 120 min before 
administration of methamphetamine (1 mg/kg s.c.). 
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Figure 9. mGluR2 PAM oxazoles: imidazooxazoles 
 
 
6.5. Oxazolopyrimidones 
 
Scientists at Sanofi have also been active in the search of new mGluR2 PAMs from the year 
of 2008 to 2011. In this four year period 5 patent applications have been published, 
describing oxazolopyrimidones, structurally related to previously reported 
oxazolidinones/oxazolobenzimidazoles (Figure 10). The first application discloses 
oxazolopyrimidone derivatives, substituted with alkyl substituted aryloxymethyl groups at C-
2, where the R configuration also largely preferred [92]. Exemplified compounds showed 
EC50 values between 0.5 nM and 3 µM in a FLIPR assay, but no specific data are given, as in 
case of compound 45. The second case describes tricyclic oxazolopyrimidones, as 
exemplified with compound 46, with EC50 values between 0.5 nM and 3 µM [93]. In 2011 
Sanofi published three new patent applications describing the close analogues of the 
previously reported dihydro oxazolopyrimidinones [94,95,96]. These compounds have 
favorable pharmacological properties as previously reported derivatives, as mGluR2 PAM 
potency and ADME properties. The first new application discloses para-biphenyloxymethyl 
derivatives [94]. The preferred compound of this invention is 47, having an ethyl side chain 
at C-5. This compound is a potent mGluR2 PAM with an EC50 value of 19 nM in a FLIPR assay. 
In the second case benzocycloalkyloxymethyl derivatives were used at C-2 [95]. These 
analogues showed improved potency, as exemplified with compound 48. The last application 
discloses aryloxymethyl derivatives at C-2 [96]. Preferred compounds have EC50 values 
between 1 and 100 nM, as compound 49. 
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Figure 10. mGluR2 PAM oxazolopyrimidones 
 
 
7. Benzazoles 
 
7.1. Indoles 
 
The first application, describing benzazole derivatives was published by Merck in 2006 [97]. 
The invention includes indoles, benzotriazoles, benzisoxazoles and indazoles. Preferred 
compounds of this application have EC50 values less than 1 µM, but no specific data is given. 
The structure–activity relationships of these derivatives have been reported in a separate 
paper [98]. The most promising compound, 49, was identified starting from a hit compound, 
3, identified by a HTS screening campaign [39,40] (Figure 11). This compound is an mGluR2-
selective PAM that is moderately brain penetrant (B/P = 0.16), has acceptable rat PK, and 
most importantly, significantly attenuated ketamine-induced hyperactivity at 40 mg/kg i.p. 
dose in rats. 
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EC50 = 559 nM (GTPS) [98]
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Figure 11. mGluR2 PAM benzazoles: indoles 
 
7.2. Benzimidazoles 
 
Benzimidazole derivatives as mGluR2 potentiators have been developed by researchers at 
AstraZeneca/NPS and Pfizer in 2007 and 2008 (Figure 12). In this two year period 5 patent 
applications have been published, describing benzimidazoles with different lipophilic side 
chains at C-2. The first application by AstraZeneca/NPS covers 117 benzimidazole examples, 
substituted typically with an aryloxyalkyl piperidine or piperazine moiety at C-2 through a 
methylene linker [99]. The most potent compound, 50, has an EC50 value of 57 nM in a 
GTPγS assay. Pfizer also disclosed similar benzoimidazoles, in these cases aryl piperidine 
[100] and aryl [3.1.0.]azabicyclic ring systems [101] were used as lipophilic side chains at C-2, 
as exemplified with compound 51 (FLIPR EC50 = 7 nM) and 52 (FLIPR EC50 = 26 nM). These 
lipophilic side chains were also used and covered by Pfizer in two separate patent 
applications describing azabenzimidazoles. Compounds 53 [102] and 54 [103] are preferred 
examples with EC50 values of 27 nM and 36.9 nM, respectively. Detailed SAR and rat 
pharmacokinetic properties of azabicyclic derivatives are described in a separate publication 
[104].  
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Figure 12. mGluR2 PAM benzazoles: benzimidazoles 
 
 
7.3. Benzotriazoles 
 
Benzotriazole derivatives have been published by Merck in eight patent applications as 
mGluR2 potentiators (Figure 13). The initiate series describes 1,2,3-benzotriazoles, 
substituted with benzyl amines or benzamides at C-5; halogen, methyl and cyano groups at 
C-4 and alkyl or cycloalkyl moieties at N-1 [105]. Compound 55 is the most potent example 
of this application with an EC50 value of 15 nM in a FLIPR assay. The second application 
discloses arylbenzotriazoles [106]. Preferred compounds contains aryl or heteroaryl 
substituents at C-5, bromo or chloro substituent at C-4 and tert-butylmethyl and 
cyclopropylmethyl groups at N-1 as exemplified with compound 56 as the most potent 
(FLIPR EC50 = 8 nM) derivative. Another series, called benzotriazole-ethers are reported in 
two patent applications [107,108] in 2011 and 2012. The first series [107] describes 1,2,3-
benzotriazoles substituted with aryl or heteroaryl ethers at C-5 with the same preferred 
substituents at C-4 and N-1 as previously reported [105, 106]. Compound 57 in Figure 13 is 
reported as the most potent one (FLIPR EC50 = 2 nM). The second application discloses 424 
examples with alkylether substituents at C-5 [108]. Compound 58 is a preferred example 
with an EC50 value of 3.5 nM. In 2012 four new benzotriazole derivatives were published by 
Merck. These applications seem to be the result of the optimization program of Merck, 
focusing the lipophilic side chain at C-5. 4-aminomethylphenyl- and 4-aminomethylpyridin-3-
yl [109], 4-hydroxymethylphenyl- [110], cyclohexenyl- [111] and alkynyl- [112] substituents 
at C-5 of the benzotriazole core were identified as potent mGluR2 PAMs. Compounds 59, 60, 
61 and 62 are the most potent representatives from these new series (Figure 13).  
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EC50 = 4.8 nM (FLIPR)
 
Figure 13. mGluR2 PAM benzazoles: benzotriazoles 
 
 
8. Benzazolones 
 
8.1. Benzimidazolones 
 
In 2011 and 2012 researchers at Merck have published four new patent applications 
describing benzimidazolones and the analogue 3-methyl-imidazopyridin-2-one derivatives; 
structurally related to previously reported benzotriazoles (Figure 14). The initiate application 
discloses aminosubstituted imidazopyridinones [113]. Preferred aminosubstituents at C-5 of 
the core are piperidines and piperazines as in the case of the most potent example, 63 (FLIPR 
EC50 = 29 nM). Aryl and heteroaryl derivatives at C-5 of imidazopyridinones have disclosed in 
a separate application [114].  This application covers 523 examples generally with EC50 
values less than 3 µM in a FLIPR assay as represented by the most potent compound, 64 
(FLIPR EC50 = 8 nM), in Figure 14. Another series of imidazopyridinones have been published 
in 2012 [115]. This application discloses aminoalkyl or alkyl substituents at C-5 and large 
lipophilic substituents at N-1, preferably tert-butylmethy- and 2,2-difluorocyclopropylmethyl 
groups, as exemplified by compound 65 with an EC50 value of 16 nM in a FLIPR assay.  
The last patent application from this series was published in 2012 describing 
benzimidazolones [116]. Preferred substituents were chosen from the previously reported 
[114] lipophilic side chains at C-5. Compounds of this invention are reported to have EC50 
values less than 10 µM in a FLIPR assay. Compound 66 is the most potent one (FLIPR EC50 = 
40 nM) exemplified in this patent application (Figure 14).  
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Figure 14. mGluR2 PAM benzazolones: benzimidazolones 
 
 
8.2. Benzothiadiazole-dioxides 
 
1,3-dihydro-2,1,3-benzothiadiazole-2,2-dioxides, structurally related to the 
benzimidazolone/3-methyl-imidazopyridin-2-one series have also been published by Merck 
in 2011 [117] exemplified by compounds substituted with aryl or heteroaryl groups at C-5 
and lipophilic substituents (preferably 2,2-difluorocyclopropylmethyl) at N-1. Preferred 
examples show EC50 values less than 1.5 µM in both FLIPR and GTPγS assays. Compound 67 
is one of the most potent ones (FLIPR EC50 = 0.8 nM) exemplified in this patent application in 
Figure 15.  
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Figure 15. mGluR2 PAM benzazolones: benzothiadiazole-dioxides 
 
 
8.3. Benzothiazolones 
 
Benzothiazolone derivatives with the previously reported [117] lipophilic side chains at C-5 
of the central core were published separately by Merck in 2011 [118]. Preferred examples 
show EC50 values less than 3 µM. Compound 68 in Figure 16 is the representative example in 
this application with an EC50 value of 15 nM in a FLIPR assay.  
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Figure 16. mGluR2 PAM benzazolones: benzothiazolones 
 
 
9. Imidazopyridines 
 
Janssen has discovered an interesting series of imidazopyridines as mGluR2 potentiators 
based on the bioisosteric replacement of the previously reported pyridone core [119]. The 
first patent application is the combination of the imidazopyridine core and the previously 
reported lipophilic side chains at C-7 [120]. Preferred compounds are amino- and 
arylimidazopyridines, exemplified with compound 69 and 70, with EC50 values of 10 nM and 
150 nM, respectively (Figure 17). In a second application, indole- and benzoxazine 
derivatives at C-7 of the imidazopyridine core were described [121]. Compound 71 is a 
representative example in this application. Detailed SAR and optimization of the 
imidazopyridine series with a more optimal oral PK profile has been reported in a separate 
paper [122]. Compound 71 was identified showing good potency (GTPγS EC50 = 85 nM) and 
good selectivity for the mGluR2 receptor, as well and with an improved oral PK profile. 
Compound 71 also modulated REM 
sleep variables in a rat sleep model, a mechanism of action that is consistent with mGluR2 
receptor activation.  
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Figure 17. mGluR2 PAM imidazopyridines 
 
 
10. Triazolopyridines 
 
A series of triazolopyridines closely-related to imidazopyridine derivatives were also 
disclosed in several patent applications from Janssen/Addex (Figure 18). The initial series 
discloses triazolopyridines, substituted with heterobicyclic rings at C-7 and alkyl side chains 
at C3, as commonly used lipophilic moieties at this region [123].  Detailed pharmacological 
data are given for some examples, as in the case of compound 72 in Figure 18. Compound 72 
is a potent mGluR2 PAM with an EC50 value of 11 nM in a GTPγS binding assay. Compound 72 
was active in a PCP-HL assay in mice with an ED50 value of 13.2 mg/kg s.c. and found to be 
also active in the conditioned avoidance response (CAR) test in rats (ED50 = 20 mg/kg, s.c., 
ED50 < 40 mg/kg, i.p.).  
Aryl substituted derivatives at C-7 of the triazolopyridine core were published in a separate 
patent application [124]. Detailed in vivo data (PCP-HL, CAR and amphetamine-induced 
hyperlocomotion) were also given for some examples. Compound 73 is a representative 
example from this application (GTPγS EC50 = 50 nM; Mice PCP-HL ED50 = 18.7 mg/kg, s.c.; Rat 
CAR ED50 = 21.4 mg/kg, p.o.; Amp.ind. HL ED50 = 28.3 mg/kg).  
In a third application amino substituted triazolopyridines were described [125]. Also in this 
case in vivo data are provided for some examples, such as compound 74 (GTPγS EC50 = 17 
nM; Mice PCP-HL ED50 = 5.4 mg/kg, s.c.; Rat CAR ED50 = 2.35 mg/kg, s.c.). The optimization of 
the triazolopyridine chemotype starting from the imidazopyridines is published in a separate 
paper in 2012 [126]. Compound 74, also known as JNJ42153605 was identified as the most 
potent derivative, showing a central in vivo efficacy by inhibition of REM sleep state at a 
dose of 3 mg/kg p.o. in the rat sleep−wake EEG paradigm. 
Further three patent applications from the triazolopyridine series were published in 2012 
describing different aminomethyl substituents at C-7. Representative examples of these 
inventions are compounds 75 [127], 76 [128], and 77 [129] with EC50 values of 38 nM, 170 
nM and 2.5 nM, respectively. In 2012 Janssen published a patent application claiming 
radiolabeled triazolopyridines as mGluR2 PET ligands [130] and the profile and properties of 
these ligands are also published in a separate paper [131].  
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Figure 18. mGluR2 PAM triazolopyridines 
 
 
 
11. Other scaffolds 
 
11.1. Benzosulphonamides 
 
A large series (124 examples) of benzosulphonamides was described by AstraZeneca/NPS as 
mGluR2 potentiators in 2004 [132]. Compounds exemplified in this application are benzoic 
acid ester derivatives at C-1, substituted typically with methyl and chloro substituent at C-2 
and C-4. Compounds are indicated to have mGluR2 PAM EC50 values less than 10 µM, but no 
specific potency data are given. Compound 78 is a representative structure of the 
benzosulphonamide series (Figure 19).  
 
11.2. Pyrazolones 
 
In 2006 AstraZeneca/NPS have disclosed a novel chemical series in a large patent application 
[133]. This case discloses pyrazolone derivatives, substituted with a piperidine or piperazine 
at C-5 and a phenyl ring at C-2 as exemplified with compound 79. Potency data are not 
provided (Figure 19). 
 
11.3. Thienopyrimidines 
 
In 2004, Janssen/Addex published a patent application detailing 2,4-disubstituted 
thienopyrimidine derivatives as mGluR2 potentiators [134]. Compounds of this application 
are typically substituted with a methyl or propyl group at C-2 and a benzylamino group at C-
4. Preferred compounds are noted to have EC50 values less than 10 µM in a GTPγS binding 
assay. A representative compound (80) from this application is shown in Figure 19.  
 
11.4. Imidazolones 
 
In 2013, a large series (188 examples) of imidazolones has been published by Taisho [135]. 
The substitution pattern around the imidazolone core are substituted phenyl at C-3, small 
substituents, preferably methyl at C-2 and lipophilic alkyl- and cycloalkyl at N-3. Potency 
data are given for all examples, among which compound 81 showed the best potency with 
an EC50 value of 2.7 nM in a GTPγS binding assay (Figure 19).   
 
11.5. Dihydroimidazopyrazinones 
 
In 2013, Dainippon Sumitomo published a patent application describing dihydroimidazo 
pyrazinones [136]. Compounds of this application are typically substituted with a chloro at C-
2, an aryl group at C-3 and alkyl- or cycloalkyl groups at N-1. An exemplified compound, 82, 
showed positive modulator activity at human mGluR2 stably expressed in HEK cells by 63, 70 
and 91% at 0.1, 1 and 10 µM, respectively (Figure 19). 
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Figure 19. mGluR2 PAM benzosulphonamides, pyrazolones, thienopyrimidines, imidazolones 
and dihydroimidazopyrazolones 
 
 
Conclusion 
Collecting data on the medicinal chemistry of mGluR2 positive allosteric modulators we 
conclude that a number of chemotypes have been found. The compounds reported up to 
now show high efficacy on the target and some chemical series fulfill general drug likeness 
criteria. The evaluation of mGluR2 PAM compound classes was completed by the 
assessment of ligand efficiency analysis performed on compounds available from the 
Thomson Reuters Integrity database [137]. Ligand efficiency (LE) [138], ligand lipophilicity 
efficiency (LLE) [139] and ligand-efficiency-dependent lipophilicity (LELP) [140] values were 
calculated and compounds were depicted in the LE-LLE and LLE-LELP spaces.  
 
 
 
 
 
 
 
Figure 20. Ligand efficiency (LE) versus lipophilic ligand efficiency (LLE) plot for mGluR2 PAM 
compounds (n = 271;LE and LLE values were calculated from half-maximal effective 
concentration (EC50) values). 
 
A recent analysis of compounds developed against a high number of drug target revealed 
that promising drug candidates have LE>0.3 and LLE>5 that defines a preferred region of the 
LE-LLE space [141]. Compounds located in this region have typically higher chance reaching 
the clinic than those fail to achieve these criteria. Furthermore the authors claimed that the 
percentage of compounds within this area indicates the chemical tractability of the drug 
target. Analyzing the mGluR2 PAMs in the LE-LLE space (Figure 20) we found that the 
majority of the compounds have both suboptimal LE and LLE values suggesting mGluR2 
being a challenging target from medicinal chemistry point of view.  It seems that reaching 
the LE criterion of 0.3 is somewhat easier than fulfilling LLE>5 indicating that the PAM site of 
mGluR2 is rather lipophilic. There were only three compounds in the most preferred region 
of the LE-LLE plot all claimed by Pfizer in 2007. These azabenzimidazoles are the results of a 
lead optimization program, starting from the original benzimidazole scaffold identified in an 
HTS campaign. Interestingly, introduction of pyridyl nitrogens could improve 
physicochemical and ADME properties and was also well tolerated for mGluR2 potency for 4- 
(compound 83 and 84) and 5-azabenzimidazoles (compound 85) (Figure 21) [103,104]. 
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Figure 21. The most promising mGluR2 positive allosteric modulators identified on the LE-LLE 
and the LLE-LELP plots. 
 
Another analysis of drug discovery compounds from different development stages 
concluded that marketed drugs and Phase II compounds have typically LLE>5 and LELP<10 
[142]. This observation was in line with a Pfizer study concluding that compounds having 
LELP>10 have much higher chance for attrition during clinical development [143].  
 
 
 
Figure 22. Ligand lipophilicity efficiency (LLE) [139] and ligand-efficiency-dependent 
lipophilicity (LELP) plot for mGluR2 PAM compounds (n = 271;LLE and LELP values were 
calculated from half-maximal effective concentration (EC50) values). 
 
 
The analysis of mGluR2 PAM compounds in the LLE-LELP space (Figure 22) revealed that the 
vast majority of published compounds fail to meet both LLE>5 and LELP<10 criteria. We 
identified only five compounds located in the desired area of the LLE-LELP plot (Figure 21). 
The most attractive series based on LELP-LLE values are described by Pfizer (compound 84 
and 85 also favoured by the LE-LLE plot ), AstraZeneca (compound 86), Merck (compound 
87) and Taisho (compound 88). Isoindolone derivatives as mGluR2 ligands were first 
described by AstraZeneca. The hit to lead optimization around this scaffold resulted in 10 
patent applications. Compound 86 is an example of the last disclosure [69] claiming 21 
specific examples.  With the combination of the earlier introduced and claimed less lipophilic 
end-groups, a successful effort was made to find the best quality compounds of this 
isoindolone class. Compound 87 from Merck Laboratories [106] is also a great example for 
balanced optimization of potency and ADME profile in the benzotriazole class claimed in 8 
patent applications. Compound 88 from Taisho, an imidazolone derivative is a newly 
published [135] mGluR2 chemotype with attractive lipophilic efficiencies. 
These analyses of available mGluR2 PAM compounds revealed that despite of the lipophilic 
character of the PAM binding site some of the compound series fulfill the ligand efficiency 
criteria of development candidates. These compound classes were identified by a number of 
pharmaceutical companies having the potential to push compounds from these series into 
clinical development.  
Although the leading orthosteric agonist LY2140023 has failed to show robust efficacy in 
clinical trials several companies have still significant interest in the target. Activation of 
mGluR2 receptors could be achieved via allosteric modulation as has been demonstrated in 
preclinical functional studies. This approach might demonstrate considerable advantages 
over orthosteric activation. First, there is higher chance to achieve selectivity over mGluR3 
receptors. Second, allosteric modulators are only effective in the presence of glutamate that 
would prevent receptor desensitization that is often the case with orthosteric agonists. Third, 
positive allosteric modulators might use different signaling pathways transforming mGluR2 
receptors into its activated state. Utilizing the principles of functional selectivity several 
subtypes of positive allosteric modulators might be considered and tested in experimental 
disease models. Finally, positive modulators could realize their functional effects as pure 
PAMs but also as ago-PAMS when compounds show inherent agonistic activity over their 
allosteric modulatory effect. Although it is not clear whether pure PAMs or ago-PAMs are 
better in disease models, this phenomena together with the proposed functional selectivity 
represents further opportunities optimizing the molecular mechanism of action for targeted 
indications. Considering one of the major indications, schizophrenia the effect of PAMs is 
proposed to be mediated via the mGluR2-5HT2A functional heterodimer. It has been shown 
that mGluR2 activation causes suppression of 5-HT2A-mediated signaling events due to 
protein-protein interactions [71,72]. Moreover, the responses elicited by hallucinogenic and 
non-hallucinogenic 5-HT2A agonists seem to differ in the intracellular signaling pathways 
involved [73, 74] and mGluR2 activation might suppress the hallucinogenic pathway [71]. 
Interestingly, preliminary pharmacogenetic analysis of subjects treated with LY2140023 
revealed a strong correlation between treatment response and 5-HT2A genotype of the 
patients [75]. Based on the above observations it is assumed that potentiation of 
endogenous mGluR2 activity with subtype-selective positive allosteric modulators would 
specifically augment the suppression of hallucinogenic 5-HT2A signaling and thus might offer 
an effective therapy for schizophrenia by attenuation of cortical overexcitation. Since 
mGluR2 PAMs might have diverse impact on the functional heterodimers this offers further 
opportunities for selecting allosteric modulators being most effective on heterodimers. 
Considering the multiple options in molecular mechanisms of action and the high number of 
chemotypes available we think that further research is needed to define the most effective 
approach against mGluR2 receptor related indications. We hypothesize that these 
indications might need different approaches that should be selected in preclinical disease 
models. This work of course implies the detailed in vitro functional characterization 
(functional activity in different paradigms, selectivity, receptor sensitization, signaling 
pathways, effect on heterodimers etc.) of a wide range of chemotypes including those 
actually investigated in clinical trials. We are more than confident that the publication of 
clinical data collected for ADX-71149 (JNJ-4041183) would facilitate further research on 
mGluR2 positive allosteric modulators. The community is looking forward to these data since 
positive results might encourage further companies pushing their mGluR2 PAM programs 
further in their clinical pipeline. In other scenarios, however, further research would clarify 
the impact of molecular mechanisms of activation in mGluR2 related indications.   
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